---
title: Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
nct_id: NCT06269302
overall_status: COMPLETED
sponsor: Samsun Education and Research Hospital
study_type: OBSERVATIONAL
primary_condition: Anticoagulants and Bleeding Disorders
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06269302.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06269302"
ct_last_update_post_date: 2024-02-21
last_seen_at: "2026-05-12T07:11:03.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparison of the Effect of Warfarin and Direct Oral Anticoagulants

**Official Title:** Comparison of the Effect of Warfarin and Direct Oral Anticoagulants on Upper Gastrointestinal System Bleeding

**NCT ID:** [NCT06269302](https://clinicaltrials.gov/study/NCT06269302)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 346
- **Lead Sponsor:** Samsun Education and Research Hospital
- **Conditions:** Anticoagulants and Bleeding Disorders, Gastrointestinal Hemorrhage
- **Start Date:** 2022-01-01
- **Completion Date:** 2022-12-31
- **CT.gov Last Update:** 2024-02-21

## Brief Summary

In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper gastrointestinal bleeding

## Detailed Description

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine with a diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy between 01.01.2021 and 31.12.2021 were included. The patients' data were analyzed from the patient files and hospital automation system retrospectively. Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of the new generation oral anticoagulants usage in patients with re-bleeding was determined, and data such as re-bleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it. The patient demographics were also compared between the groups who were using the new generation oral anticoagulants, acetylsalicylic acid or warfarin.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \>18 years old
* Upper gastrointestinal bleeding
* 12 months follow-up

Exclusion Criteria:

* Age \<18 years old
* Lower gastrointestinal bleeding
* Esophageal variceal bleeding
```

## Arms

- **Patients with recurrent gastrointestinal bleeding** — The data of all patients who applied to Samsun Training and Research Hospital for 12 months in 2022 and diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of use of new generation oral anticoagulants in patients with rebleeding was determined, and data such as rebleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it.

## Primary Outcomes

- **Change in the incidence of recurrent bleeding** _(time frame: 12 months)_ — Increase or decrease in the incidence of recurrent bleeding

## Locations (1)

- Samsun Education and Research Hospital, Samsun, İlkadım, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsun education and research hospital|samsun|i̇lkadım|turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06269302.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06269302*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*